Summary & Overview
HCPCS Level II J9356: Trastuzumab with Hyaluronidase, Subcutaneous Injection
HCPCS Level II code J9356 represents a subcutaneous formulation of trastuzumab combined with hyaluronidase (10 mg per unit) used in oncology care. The code identifies a biologic injectable therapy administered to patients who require HER2-directed treatment, and it matters nationally as trastuzumab products are central to breast and gastric cancer management and drive notable oncology drug spending and site-of-care decisions. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what this code denotes clinically and operationally, how it aligns with outpatient and office-based subcutaneous administration, and the payer landscape relevant to coverage and billing practice. The publication summarizes available benchmarks for utilization and reimbursement, notes common billing and coding considerations for administration in ambulatory oncology settings, and outlines policy and regulatory contexts that affect access and payment for trastuzumab subcutaneous formulations. Data gaps from the input are identified where applicable; specifics on modifiers, associated taxonomies, ICD-10 pairings, and related codes are not provided in the source and are noted as unavailable.
Billing Code Overview
HCPCS Level II code J9356 describes an injection of trastuzumab, 10 mg, combined with hyaluronidase-oysk. This HCPCS entry corresponds to a biologic oncology therapy formulation administered as a subcutaneous injection that pairs the monoclonal antibody trastuzumab with a hyaluronidase enzyme to facilitate dispersion.
Service type: Injectable oncology/antineoplastic administration
Typical site of service: Outpatient infusion clinic, oncology clinic, or physician office for subcutaneous administration
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult female with HER2-positive early-stage or metastatic breast cancer receiving subcutaneous trastuzumab with hyaluronidase-oysk for targeted HER2 therapy. The patient presents to an oncology infusion clinic or outpatient oncology suite for administration. Pre-visit workflow includes verification of diagnosis, review of prior trastuzumab exposure and cardiac function (echocardiogram or MUGA within guideline-specified intervals), medication reconciliation, and assessment for hypersensitivity history. On the day of service, nursing performs site assessment, obtains informed consent, confirms chemotherapy orders, prepares J9356 dosing based on provider orders (expressed per 10 mg units), and administers subcutaneous injection in the upper abdomen or thigh per product instructions. Observation follows for acute reactions; documentation includes lot number, expiration, administered dose, route, site, and any immediate adverse events. Billing uses J9356 to report trastuzumab and hyaluronidase-oysk as a combined subcutaneous product; relevant modifiers may be appended to indicate professional/technical components, discontinued services, or drug waste as clinically applicable. Typical sites of service are outpatient hospital clinic, physician office, or ambulatory infusion center. Typical associated clinical team includes medical oncologist (orders), oncology nurse (administration), pharmacist (verification and preparation), and cardiovascular team for baseline and surveillance imaging when indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|